CXCL11 (interferon-inducible T-cell alpha chemoattractant) and interleukin-18 in relapsing-remitting multiple sclerosis patients treated with methylprednisolone

European Neurology

Volumn 58, Issue 4, 2007, Pages 228-232

  Szczuciński, Adam ^a   Kalinowska, Alicja ^b   Losy, Jacek ^a,c  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b University Hospital 2   (Poland)

^c POLISH ACADEMY OF SCIENCES   (Poland)

Author keywords

Interferon inducible T cell chemoattractant; Interleukin 18; Methylprednisolone; Multiple sclerosis

Indexed keywords

CXCL11 CHEMOKINE; INTERLEUKIN 18; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE;

ADULT; ARTICLE; BLOOD BRAIN BARRIER; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATION; MALE; MULTIPLE SCLEROSIS; PATHOGENESIS; PRIORITY JOURNAL; RELAPSE; REMISSION; TH1 CELL;

ADULT; CHEMOKINE CXCL11; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-18; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEUROPROTECTIVE AGENTS; STATISTICS, NONPARAMETRIC;

EID: 36448984951     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000107945     Document Type: Article

References (29)

1. Compston A, Coles A: Multiple sclerosis. Lancet 2002;359:1221-1231.
2. Frohman EM, Racke MK, Raine CS: Multiple sclerosis - the plaque and its pathogenesis. N Engl J Med 2006;354:924-955.
3. Imitola J, Chitnis T, Khoury SJ: Cytokines in multiple sclerosis: from bench to bedside. Pharmacol Ther 2005;106:163-177.
4. Ziemssen T, Ziemssen F: The role of the humoral immune system in multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE). Autoimmun Rev 2005;4:460-467.
5. Balashov KE, Rottman JB, Weiner HL, Hancock WW: CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci USA 1999;96:6873-6878.
6. Panitch HS, Hirsch RL, Haley AS, Johnson KP: Exacerbation of multiple sclerosis in patients treated with gamma interferon. Lancet 1987;1:893-895.
7. Petereit HF, Richter N, Pukrop R, Bamborschke S: Interferon gamma production in blood lymphocytes correlates with disability score in multiple sclerosis patients. Mult Scler 2000;6:19-23.
8. Losy J, Niezgoda A: IL-18 in patients with multiple sclerosis. Acta Neurol Scand 2001;102:171-173.
9. Kodama M, Takahashi HK, Iwagaki H, Itoh H, Morichika T, Yoshida A, Yoshioka H, Morimoto Y, Nishibori M, Tanaka N: Effect of steroids on lipopolysaccharide/interleukin 2-induced interleukin 18 production in peripheral blood mononuclear cells. J Int Med Res 2002;30:144-160.
10. Charo IF, Ransohoff RM: The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006;354:610-621.
11. Szczuciński A, Losy J: Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies. Acta Neurol Scand 2007;115:137-146.
12. Simpson JE, Newcombe J, Cuzner ML, Woodroofe MN: Expression of the interferon-gamma-inducible chemokines IP-10 and Mig and their receptor, CXCR3, in multiple sclerosis lesions. Neuropathol Appl Neurobiol 2000;26:133-142.
13. Sørensen TL, Tani M, Jensen J, Pierce V, Lucchinetti C, Folcik VA, Oin S, Rottman J, Sellebjerg F, Strieter RM, Frederiksen JL, Ransohoff RM: Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 1999;103:807-815.
14. Luster AD, Unkeess JC, Ravetch JV: Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature 1985;315:672-676.
15. Loetscher P, Pellegrino A, Gong JH, Mattioli I, Loetscher M, Bardi G, Baggiolini M, Clark-Lewis I: The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3. J Biol Chem 2001;276:2986-2991.
16. Mahad DJ, Lawry J, Howell SJL, Woodroofe MN: Longitudinal study of chemokine receptor expression on peripheral lymphocytes in multiple sclerosis: CXCR3 upregulation is associated with relapse. Mult Scler 2003;9:189-198.
17. Suliman O, Sharrack B, Woodroofe N: Expression of chemokine receptors by peripheral blood mononuclear cells in multiple sclerosis. Mult Scler 2006;12(suppl 1):S220-S221.
18. Sindern E, Patzold T, Ossege LM, Gisevius A, Malin JP: Expression of chemokine receptor CXCR3 on cerebrospinal fluid T-cells is related to active MRI lesion appearance in patients with relapsing-remitting multiple sclerosis. J Neuroimmunol 2002;131:186-190.
19. Sørensen TL, Sellebjerg F, Jensen CV, Strieter RM, Ransohoff RM: Chemokines CXCL10 and CCL2: differential involvement in intrathecal inflammation in multiple sclerosis. Eur J Neurol 2001;8:665-672.
20. Franciotta D, Martino G, Zardini E, Furlan R, Bergamaschi R, Andreoni L, Cosi V: Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies. J Neuroimmunol 2001;115:192-198.
21. Xie JH, Nomura N, Lu M, Chen SL, Koch GE, Weng Y, Rosa R, Di Salvo J, Mudgett J, Peterson LB, Wicker LS, DeMartino JA: Antibody-mediated blockade of the CXCR3 chemokine receptor results in diminished recruitment of T helper 1 cells into sites of inflammation. J Leukoc Biol 2003;73:771-780.
22. Lepej SŽ, Mišić-Majernus L, Jeren T, Rode OD, Remenar A, Sporec V, Vince A: Chemokines CXCL10 and CXCL11 in the cerebrospinal fluid of patients with tick-borne encephalitis. Acta Neurol Scand 2007;115:109-114.
23. Lepej SŽ, Rode OD, Jeren T, Vince A, Remenar A, Barsic B: Increased expression of CXCR3 and CCR5 on memory CD4+ T-cells migrating into the cerebrospinal fluid of patients with neuroborreliosis: the role of CXCL10 and CXCL11. J Neuroimmunol 2005;163:128-134.
24. Bartosik-Psujek H, Stelmasiak Z: Steroid therapy altered serum levels of CCL2 and CCL5 chemokines in multiple sclerosis patients during relapse. Eur Neurol 2004;52:237-241.
25. Sloka JS, Stefanelli M: The mechanism of action of methylprednisolone in the treatment of multiple sclerosis. Mult Scler 2005;11:425-432.
26. Moreira MA, Tilbery CP, Monteiro LP, Teixeira AL: Effect of the treatment with methylprednisolone on the cerebrospinal fluid and serum levels of CCL2 and CXCL10 chemokines in patients with active multiple sclerosis. Acta Neurol Scand 2006;114:109-113.
27. Elovaara I, Kuusisto H, Paalavuo R, Sarkijarvi S, Lehtimaki T, Huhtala H, Vilpo J: Effect of high-dose methylprednisolone treatment on CCR5 expression on blood cells in MS exacerbation. Acta Neurol Scand 2006;113:163-166.
28. Martinez-Caceres EM, Barrau MA, Brieva L, Espejo C, Barbera N, Montalban X: Treatment with methylprednisolone in relapses of multiple sclerosis patients: immunological evidence of immediate and short-term but not long-lasting effects. Clin Exp Immunol 2002;127:165-171.
29. Losy J, Michałowska-Wender G, Wemder M: Analysis of interleukin 18 during therapy with glatiramer acetate (Copaxone) in patients with relapsing-remitting multiple sclerosis. Folia Neuropathol 2001;39(suppl A):23-24.